Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysis

Aim The goal of this study is to evaluate the safety of diagnostic hysteroscopy (HSC) in type II endometrial cancer (EC).Methods We searched PubMed, the Cochrane Library and the Chinese Medical Journal Full-Text Database until December 2023. Eligible trials were all cohort studies in which patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenmei Yang, Xiaoqi Zhao, Jingyi Pan, Zhifu Zhi
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/10/e087582.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850062890952818688
author Wenmei Yang
Xiaoqi Zhao
Jingyi Pan
Zhifu Zhi
author_facet Wenmei Yang
Xiaoqi Zhao
Jingyi Pan
Zhifu Zhi
author_sort Wenmei Yang
collection DOAJ
description Aim The goal of this study is to evaluate the safety of diagnostic hysteroscopy (HSC) in type II endometrial cancer (EC).Methods We searched PubMed, the Cochrane Library and the Chinese Medical Journal Full-Text Database until December 2023. Eligible trials were all cohort studies in which patients were allocated to diagnostic HSC group or dilation and curettage (D&C) group. Quality assessments of eligible studies were performed using the Newcastle–Ottawa scales. Risk ratios (RRs) with 95% CIs were calculated as a measure of effects.Results Three trials were included in our analysis, which were all retrospective cohort studies. 696 patients with histologically proven type II EC were allocated to HSC or D&C before surgery. 257 patients underwent preoperative HSC, and 439 patients underwent D&C. The positive peritoneal cytology rate did not statistically differ between the groups (RR, 1.9; 95% CI, 1.00 to 3.61; p=0.05). There was no significant difference in the incidence of International Federation of Gynecology and Obstetrics (FIGO) stage between the HSC and D&C groups (stage I/II: RR, 1.08; 95% CI, 0.95 to 1.24; p=0.25; stage III/IV: RR, 0.82; 95% CI, 0.62 to 1.09; p=0.18). There was no significant difference in recurrence between the HSC and D&C groups (RR, 0.92; 95% CI, 0.66 to 1.32; p=0.66); the heterogeneity of the two included studies was acceptable (p=0.54, I2=0%).Conclusions Preoperative HSC in patients with type II EC does not increase the risk for cancer cell dissemination within the peritoneal cavity. Preoperative HSC does not progress the FIGO staging in patients with type II EC and does not increase the risk of tumour recurrence. There is no reason to avoid HSC for the diagnosis of type II EC currently. However, type II tumours generally are less well differentiated and have poorer prognoses than type I tumours. More prospective and adequately powered trials are required to clarify whether preoperative HSC in patients with type II EC is safe.
format Article
id doaj-art-bcb009404fc045b3ba08e627fa3930d2
institution DOAJ
issn 2044-6055
language English
publishDate 2024-10-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-bcb009404fc045b3ba08e627fa3930d22025-08-20T02:49:48ZengBMJ Publishing GroupBMJ Open2044-60552024-10-01141010.1136/bmjopen-2024-087582Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysisWenmei Yang0Xiaoqi Zhao1Jingyi Pan2Zhifu Zhi31 The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China2 Guangxi Medical University, Nanning, Guangxi, China2 Guangxi Medical University, Nanning, Guangxi, China3 Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaAim The goal of this study is to evaluate the safety of diagnostic hysteroscopy (HSC) in type II endometrial cancer (EC).Methods We searched PubMed, the Cochrane Library and the Chinese Medical Journal Full-Text Database until December 2023. Eligible trials were all cohort studies in which patients were allocated to diagnostic HSC group or dilation and curettage (D&C) group. Quality assessments of eligible studies were performed using the Newcastle–Ottawa scales. Risk ratios (RRs) with 95% CIs were calculated as a measure of effects.Results Three trials were included in our analysis, which were all retrospective cohort studies. 696 patients with histologically proven type II EC were allocated to HSC or D&C before surgery. 257 patients underwent preoperative HSC, and 439 patients underwent D&C. The positive peritoneal cytology rate did not statistically differ between the groups (RR, 1.9; 95% CI, 1.00 to 3.61; p=0.05). There was no significant difference in the incidence of International Federation of Gynecology and Obstetrics (FIGO) stage between the HSC and D&C groups (stage I/II: RR, 1.08; 95% CI, 0.95 to 1.24; p=0.25; stage III/IV: RR, 0.82; 95% CI, 0.62 to 1.09; p=0.18). There was no significant difference in recurrence between the HSC and D&C groups (RR, 0.92; 95% CI, 0.66 to 1.32; p=0.66); the heterogeneity of the two included studies was acceptable (p=0.54, I2=0%).Conclusions Preoperative HSC in patients with type II EC does not increase the risk for cancer cell dissemination within the peritoneal cavity. Preoperative HSC does not progress the FIGO staging in patients with type II EC and does not increase the risk of tumour recurrence. There is no reason to avoid HSC for the diagnosis of type II EC currently. However, type II tumours generally are less well differentiated and have poorer prognoses than type I tumours. More prospective and adequately powered trials are required to clarify whether preoperative HSC in patients with type II EC is safe.https://bmjopen.bmj.com/content/14/10/e087582.full
spellingShingle Wenmei Yang
Xiaoqi Zhao
Jingyi Pan
Zhifu Zhi
Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysis
BMJ Open
title Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysis
title_full Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysis
title_fullStr Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysis
title_full_unstemmed Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysis
title_short Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysis
title_sort safety of diagnostic hysteroscopy for the investigation of type ii endometrial cancer systematic review with meta analysis
url https://bmjopen.bmj.com/content/14/10/e087582.full
work_keys_str_mv AT wenmeiyang safetyofdiagnostichysteroscopyfortheinvestigationoftypeiiendometrialcancersystematicreviewwithmetaanalysis
AT xiaoqizhao safetyofdiagnostichysteroscopyfortheinvestigationoftypeiiendometrialcancersystematicreviewwithmetaanalysis
AT jingyipan safetyofdiagnostichysteroscopyfortheinvestigationoftypeiiendometrialcancersystematicreviewwithmetaanalysis
AT zhifuzhi safetyofdiagnostichysteroscopyfortheinvestigationoftypeiiendometrialcancersystematicreviewwithmetaanalysis